Drug Type Small molecule drug |
Synonyms- |
Target |
Action inhibitors |
Mechanism 17β-HSD13 inhibitors(17-beta-hydroxysteroid dehydrogenase 13 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H17F3N2O3S |
InChIKeyAIWDKLNTVXJNNU-YUMQZZPRSA-N |
CAS Registry3085644-91-0 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Liver Diseases | Preclinical | United States | 10 Jun 2025 |





